Caribou Biosciences, Inc. (CRBU) stock
CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3074% below fair value
$0.34−0.01 (-3.43%)
Close on Nov 17, 2026Market cap $36.53MP/E –Yield –
Caribou Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Caribou Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$95.78M. For fiscal 2025 it was -$110.99M. The highest annual figure on record is -$32.01M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$110.99M | – |
| FY2024 | Dec 31, 2024 | -$138.20M | – |
| FY2023 | Dec 31, 2023 | -$93.29M | – |
| FY2022 | Dec 31, 2022 | -$90.97M | – |
| FY2021 | Dec 31, 2021 | -$32.52M | – |
| FY2020 | Dec 31, 2020 | -$33.22M | – |
| FY2019 | Dec 31, 2019 | -$32.01M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$22.79M | – |
| Q1 FY2026 | Mar 31, 2026 | -$26.98M | – |
| Q4 FY2025 | Dec 31, 2025 | -$20.82M | – |
| Q3 FY2025 | Sep 30, 2025 | -$25.19M | – |
| Q2 FY2025 | Jun 30, 2025 | -$28.26M | – |
| Q1 FY2025 | Mar 31, 2025 | -$36.73M | – |
| Q4 FY2024 | Dec 31, 2024 | -$35.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.66M | – |
| Q2 FY2024 | Jun 30, 2024 | -$32.87M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.20M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$28.79M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.94M | – |
| Q4 FY2022 | Dec 31, 2022 | -$25.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.38M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.87M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.67M | -206.7% |
| Q4 FY2021 | Dec 31, 2021 | -$21.39M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.97M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.48M | – |
| Q1 FY2021 | Mar 31, 2021 | $20.31M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.08M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.69M | – |
See a number that looks wrong?